CVRx Faces Investor Lawsuit Investigation
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 30 2026
0mins
Should l Buy CVRX?
Source: Globenewswire
- Shareholder Rights Investigation: Bragar Eagel & Squire, P.C. is investigating whether CVRx has violated federal securities laws, which could impact the company's reputation and stock price significantly.
- Performance Decline Impact: On April 7, 2025, CVRx announced weaker-than-expected preliminary first-quarter results, causing its stock price to plummet from $11.54 to $6.20, a 46.3% drop, reflecting market concerns over the development of its sales representatives.
- Sales Team Changes: During the earnings call on May 8, 2025, CEO Hykes noted that 25% of territory managers were hired in a short period, indicating significant adjustments in the sales team, which further raised investor concerns about performance.
- Call for Action: Bragar Eagel & Squire encourages affected investors to contact their attorneys to understand their legal rights, demonstrating the firm's commitment to protecting shareholder interests, which may influence the outcomes of future legal actions.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CVRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CVRX
Wall Street analysts forecast CVRX stock price to rise
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 7.360
Low
11.00
Averages
12.50
High
14.00
Current: 7.360
Low
11.00
Averages
12.50
High
14.00
About CVRX
CVRx, Inc. is a commercial-stage medical device company. The Company is focused on developing, manufacturing and commercializing advanced neuromodulation solutions for patients with cardiovascular diseases. The Company's integrated platform technology, Barostim, is designed to leverage the power of the brain and nervous system to address the imbalance of the autonomic nervous system (ANS), which causes heart failure with reduced ejection fraction (HFrEF) and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy (BAT) by sending imperceptible and persistent electrical pulses to baroreceptors located in the wall of the carotid artery to signal the brain to modulate cardiovascular function. Barostim is a minimally invasive neuromodulation device that consists of two implantable components, an implantable pulse generator (IPG) and a stimulation lead, and is programmed by a wireless clinician-controlled programmer that communicates with the IPG.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
CVRx Nominates Michael Dale to Board of Directors
- New Board Member: CVRx has nominated Michael Dale to its Board of Directors, with the election scheduled for June 1, 2026, aimed at strengthening the company's leadership in cardiovascular treatment.
- Extensive Industry Experience: Dale brings a proven track record of commercial success in the medical device sector, having served as CEO of Axogen and led Abbott's structural heart division for eight years, which is expected to provide strategic support for CVRx's Barostim product promotion.
- Driving Technological Innovation: CVRx's Barostim technology is the first FDA-approved medical device that uses neuromodulation to improve heart failure symptoms, and Dale's addition is anticipated to accelerate market acceptance of this technology, driving company growth in cardiovascular treatment.
- International Certification Advantage: Barostim has received FDA Breakthrough Device designation and complies with EU Medical Device Regulation, and Dale's extensive board experience will further enhance CVRx's competitiveness and compliance in the global market.
See More
CVRx Expects 20% Revenue Growth in Q1 2026
- Revenue Growth Expectation: CVRx anticipates total revenue for Q1 2026 to be between $14.7 million and $14.8 million, representing a 20% increase from $12.3 million in Q1 2025, indicating strong market performance and growth potential.
- Gross Margin Improvement: The expected gross margin for Q1 2026 is approximately 87%, up from 84% in Q1 2025, reflecting effective strategies in cost control and product pricing.
- Increase in Operating Expenses: Total operating expenses for Q1 2026 are projected to be around $25 million, compared to $23.7 million in Q1 2025, highlighting ongoing investments in expansion and market promotion.
- Expansion of Implanting Centers: As of March 31, 2026, the number of active implanting centers in the U.S. increased to 257 from 252 as of December 31, 2025, demonstrating positive progress in market penetration and customer base expansion.
See More
CVRx Under Investigation for Possible Securities Law Violations
- Performance Decline: CVRx reported only $12.3 million in revenue for Q1 2025, and despite bringing in several high-quality sales representatives, many are still in early territory development stages, which has undermined investor confidence.
- Revenue Guidance Cut: On May 8, 2025, CVRx slashed its full-year revenue guidance to between $55 million and $58 million, with management indicating that recent changes in the salesforce were more significant than initially anticipated, raising further concerns about the company's future.
- Stock Price Plunge: Following the revenue guidance cut, CVRx's stock price plummeted by $3.01, or 38.8%, to close at $4.77 on May 9, 2025, resulting in substantial losses for investors.
- Integration Challenges: On February 12, 2026, CVRx reported its Q4 and full-year 2025 results, with management noting that integrating new representatives has created near-term growth impacts, leading to another stock price drop of $0.74, or 13.0%.
See More
Pomerantz LLP Investigates CVRx for Securities Fraud
- Securities Fraud Investigation: Pomerantz LLP is investigating CVRx and its executives for potential securities fraud or unlawful business practices, which could lead to significant losses for investors.
- Poor Performance Impact: CVRx's preliminary first-quarter results announced on April 7, 2025, fell short of expectations, causing the stock price to plummet by 46.3% to $6.20 per share on April 8, reflecting market concerns over the development of the company's sales representatives.
- Sales Team Changes: In the earnings report on May 8, 2025, CVRx lowered its full-year revenue guidance, with CEO Hykes noting that 25% of territory managers were newly hired between December and March, indicating that the impact of sales team changes was more significant than initially anticipated.
- Continued Stock Decline: Following the disappointing performance, CVRx's stock price fell again by 38.7% to $4.77 per share on May 9, 2025, highlighting a lack of investor confidence in the company's future prospects.
See More
CVRx Unveils New Data on Barostim Therapy at THT 2026
- Clinical Data Presentation: CVRx will showcase new clinical data on Barostim therapy at the 2026 Technology and Heart Failure Therapeutics meeting, featuring six-month outcomes from over 400 patients, demonstrating the therapy's safety and efficacy in heart failure patients.
- Scientific Presentations: The conference will include multiple presentations on Barostim therapy, analyzing cardiac energetics and hospitalization impacts, highlighting the therapy's potential in improving left ventricular ejection fraction (LVEF), which could set new standards in heart failure treatment.
- Satellite Program Highlights: CVRx will host a satellite program during the conference to present updates on the REBALANCE Registry data and the BREATHE-HF and BENEFIT-HF trials, the latter aiming to evaluate Barostim's impact in a significantly larger heart failure population, which holds substantial clinical significance.
- Increasing Market Acceptance: CVRx CEO Kevin Hykes noted the accelerating acceptance of Barostim within the heart failure community, with a growing number of publications validating the therapy's positive patient impact, indicating a promising expansion of market potential.
See More
Pomerantz LLP Investigates CVRx for Securities Fraud
- Securities Fraud Investigation: Pomerantz LLP is investigating claims against CVRx and its executives for potential securities fraud or unlawful business practices, which could lead to significant losses for investors.
- Poor Performance Impact: CVRx's preliminary first-quarter results released on April 7, 2025, fell short of expectations, causing the stock price to plummet 46.3% to $6.20 per share the following day, indicating market disappointment with the company's performance.
- Sales Team Changes: On May 8, 2025, CVRx announced weak first-quarter results and lowered its full-year revenue guidance, with the CEO noting that 25% of territory managers were replaced in a short period, highlighting challenges in internal restructuring.
- Continued Stock Decline: Following the poor performance and sales team changes, CVRx's stock price fell another 38.7% to $4.77 per share on May 9, 2025, reflecting investor concerns about the company's future outlook.
See More
CVRx Nominates Michael Dale to Board of Directors
- New Board Member: CVRx has nominated Michael Dale to its Board of Directors, with the election scheduled for June 1, 2026, aimed at strengthening the company's leadership in cardiovascular treatment.
- Extensive Industry Experience: Dale brings a proven track record of commercial success in the medical device sector, having served as CEO of Axogen and led Abbott's structural heart division for eight years, which is expected to provide strategic support for CVRx's Barostim product promotion.
- Driving Technological Innovation: CVRx's Barostim technology is the first FDA-approved medical device that uses neuromodulation to improve heart failure symptoms, and Dale's addition is anticipated to accelerate market acceptance of this technology, driving company growth in cardiovascular treatment.
- International Certification Advantage: Barostim has received FDA Breakthrough Device designation and complies with EU Medical Device Regulation, and Dale's extensive board experience will further enhance CVRx's competitiveness and compliance in the global market.
See More
CVRx Expects 20% Revenue Growth in Q1 2026
- Revenue Growth Expectation: CVRx anticipates total revenue for Q1 2026 to be between $14.7 million and $14.8 million, representing a 20% increase from $12.3 million in Q1 2025, indicating strong market performance and growth potential.
- Gross Margin Improvement: The expected gross margin for Q1 2026 is approximately 87%, up from 84% in Q1 2025, reflecting effective strategies in cost control and product pricing.
- Increase in Operating Expenses: Total operating expenses for Q1 2026 are projected to be around $25 million, compared to $23.7 million in Q1 2025, highlighting ongoing investments in expansion and market promotion.
- Expansion of Implanting Centers: As of March 31, 2026, the number of active implanting centers in the U.S. increased to 257 from 252 as of December 31, 2025, demonstrating positive progress in market penetration and customer base expansion.
See More
CVRx Under Investigation for Possible Securities Law Violations
- Performance Decline: CVRx reported only $12.3 million in revenue for Q1 2025, and despite bringing in several high-quality sales representatives, many are still in early territory development stages, which has undermined investor confidence.
- Revenue Guidance Cut: On May 8, 2025, CVRx slashed its full-year revenue guidance to between $55 million and $58 million, with management indicating that recent changes in the salesforce were more significant than initially anticipated, raising further concerns about the company's future.
- Stock Price Plunge: Following the revenue guidance cut, CVRx's stock price plummeted by $3.01, or 38.8%, to close at $4.77 on May 9, 2025, resulting in substantial losses for investors.
- Integration Challenges: On February 12, 2026, CVRx reported its Q4 and full-year 2025 results, with management noting that integrating new representatives has created near-term growth impacts, leading to another stock price drop of $0.74, or 13.0%.
See More
Pomerantz LLP Investigates CVRx for Securities Fraud
- Securities Fraud Investigation: Pomerantz LLP is investigating CVRx and its executives for potential securities fraud or unlawful business practices, which could lead to significant losses for investors.
- Poor Performance Impact: CVRx's preliminary first-quarter results announced on April 7, 2025, fell short of expectations, causing the stock price to plummet by 46.3% to $6.20 per share on April 8, reflecting market concerns over the development of the company's sales representatives.
- Sales Team Changes: In the earnings report on May 8, 2025, CVRx lowered its full-year revenue guidance, with CEO Hykes noting that 25% of territory managers were newly hired between December and March, indicating that the impact of sales team changes was more significant than initially anticipated.
- Continued Stock Decline: Following the disappointing performance, CVRx's stock price fell again by 38.7% to $4.77 per share on May 9, 2025, highlighting a lack of investor confidence in the company's future prospects.
See More
CVRx Unveils New Data on Barostim Therapy at THT 2026
- Clinical Data Presentation: CVRx will showcase new clinical data on Barostim therapy at the 2026 Technology and Heart Failure Therapeutics meeting, featuring six-month outcomes from over 400 patients, demonstrating the therapy's safety and efficacy in heart failure patients.
- Scientific Presentations: The conference will include multiple presentations on Barostim therapy, analyzing cardiac energetics and hospitalization impacts, highlighting the therapy's potential in improving left ventricular ejection fraction (LVEF), which could set new standards in heart failure treatment.
- Satellite Program Highlights: CVRx will host a satellite program during the conference to present updates on the REBALANCE Registry data and the BREATHE-HF and BENEFIT-HF trials, the latter aiming to evaluate Barostim's impact in a significantly larger heart failure population, which holds substantial clinical significance.
- Increasing Market Acceptance: CVRx CEO Kevin Hykes noted the accelerating acceptance of Barostim within the heart failure community, with a growing number of publications validating the therapy's positive patient impact, indicating a promising expansion of market potential.
See More
Pomerantz LLP Investigates CVRx for Securities Fraud
- Securities Fraud Investigation: Pomerantz LLP is investigating claims against CVRx and its executives for potential securities fraud or unlawful business practices, which could lead to significant losses for investors.
- Poor Performance Impact: CVRx's preliminary first-quarter results released on April 7, 2025, fell short of expectations, causing the stock price to plummet 46.3% to $6.20 per share the following day, indicating market disappointment with the company's performance.
- Sales Team Changes: On May 8, 2025, CVRx announced weak first-quarter results and lowered its full-year revenue guidance, with the CEO noting that 25% of territory managers were replaced in a short period, highlighting challenges in internal restructuring.
- Continued Stock Decline: Following the poor performance and sales team changes, CVRx's stock price fell another 38.7% to $4.77 per share on May 9, 2025, reflecting investor concerns about the company's future outlook.
See More
